MOB1A: A Potential Drug Target and Biomarker for Neurodegenerative and Autoimmune Disorders

Target Name: MOB1A

NCBI ID: G55233

MOB1A

MOB1A: A Potential Drug Target and Biomarker for Neurodegenerative and Autoimmune Disorders

MOB1A (MABKL1B), a protein that belongs to the MAB family of proteins, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. MOB1A plays a crucial role in the development and maintenance of the blood-brain barrier, which is a barrier that separates the brain from the rest of the body and is essential for the safe and effective exchange of nutrients, oxygen, and other substances into the brain.

The MAB family of proteins is characterized by the presence of a single transmembrane domain and a variable intracellular loop. MOB1A is a 14-kDa protein that is expressed in a variety of tissues, including brain, heart, liver, and muscle. It is highly conserved, with a calculated pI of 6.9 and a predicted localization in the endoplasmic reticulum (ER).

MOB1A has been shown to play a critical role in the formation and maintenance of the blood-brain barrier. The blood-brain barrier is a specialized barrier that separates the brain from the rest of the body and is designed to protect the brain from harmful substances and ensure the safe exchange of nutrients and oxygen into the brain. MOB1A is involved in the formation of the blood-brain barrier by regulating the movement of cells through the blood-brain barrier and by controlling the expression of genes involved in barrier function.

In addition to its role in the blood-brain barrier, MOB1A has also been shown to play a critical role in the development and progression of various diseases. For example, MOB1A has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. MOB1A has also been shown to be involved in the development of autoimmune disorders, including multiple sclerosis and rheumatoid arthritis.

Furthermore, MOB1A has also been shown to be a potential drug target for a variety of diseases. For example, MOB1A has been shown to be involved in the development of neurotransmitter systems, which are the chemical messengers that transmit signals through the brain. MOB1A has been shown to play a role in the regulation of neurotransmitter release and uptake, which may be important for the function of neurotransmitters in the brain. MOB1A has also been shown to be involved in the regulation of pain perception and neuroinflammation, which may be important for the development and treatment of pain and neuroinflammatory disorders.

In conclusion, MOB1A is a protein that has been shown to play a critical role in the development and maintenance of the blood-brain barrier and in the development and progression of various diseases. As a potential drug target and biomarker, MOB1A has the potential to be a valuable tool for the development and treatment of a variety of neurodegenerative and autoimmune disorders. Further research is needed to fully understand the role of MOB1A in these diseases and to develop effective treatments based on its properties.

Protein Name: MOB Kinase Activator 1A

Functions: Activator of LATS1/2 in the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS1/2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Stimulates the kinase activity of STK38 and STK38L. Acts cooperatively with STK3/MST2 to activate STK38

The "MOB1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MOB1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets